Form 4: AVITA Medical Director Equity Grant Disclosure

Director Suzanne Crowe received an equity grant of restricted stock units and stock options following shareholder approval.

Summary

• Director Suzanne Crowe was granted 22,214 restricted stock units (RSUs) and 16,133 stock options.
• The RSU grant vests one year from the January 20, 2026, grant date.
• The stock options have an exercise price of $3.77 and expire on January 20, 2036.
• These grants were contingent upon shareholder approval, which was officially obtained on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment as it reflects standard corporate governance procedures.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Successful receipt of shareholder approval for the director compensation plan.

Negatives

• Dilutive impact of new equity issuance to board members.

Risks

• Market price volatility affecting the value of the granted options and RSUs.
• Potential for future shareholder opposition to executive or director compensation packages.

Future Outlook

The equity grants are subject to standard time-based vesting, with the RSUs vesting in full on January 20, 2027, and options becoming exercisable on the same date.

Industry Context

StockSavvy.ai notes that equity-based compensation for non-executive directors is a standard corporate governance practice in the medical device sector to ensure board alignment with long-term performance goals.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for mid-cap medical technology companies.
• The grant size is typical for non-executive director compensation packages in the biotechnology and medical device industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of new equity.
• Director: Increased financial stake in the company's performance.

Next Steps

• Vesting of RSUs on January 20, 2027.
• Options become exercisable on January 20, 2027.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Director Compensation, Equity Grant, Insider Ownership